Clinical Trial Update: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ZW25 (zanidatamab) in combination chemotherapy for HER2-expressing gastrointestinal cancers, including gastroesophageal adenocarcinoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Colorectal Cancer
• Gastroesophageal Adenocarcinoma

Drugs mentioned

• ZW25 (Zanidatamab) (Zanidatamab)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | Phase 2 | Status: COMPLETED